Biotechnology companies’ fortunes depend on binary events, such as FDA approvals and clinical trials results. Drugs, devices, etc. either work or fail – with huge implications for the stock price.
This volatility opens the door to big profits, particularly in the mid or small
cap part of the sector. However, capitalizing on these opportunities depends on
knowing when the key events are going to happen.
Given there are thousands of events that can impact biotech stocks, it is difficult
for individual investors and traders to keep track of all the potential regulatory
and clinical catalysts. This can result in easily missing out on some extraordinary
investment opportunities. This is where the RTT Biotech Stocks service can help
both novice and professional investors stay ahead of the markets.
RTT tracks and monitors hundreds of companies and potential market-moving events.
These include such things as pending new drug approvals, new FDA submissions, pending
mid/early-stage clinical trial results, late-stage phase 3 clinical trial results,
FDA advisory panel meetings and much more. The RTT Biotech Stock service alerts
users ahead of key events, enabling our subscribers to take advantage of the opportunities.